Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol.
Hornschuh
B
B
Department of Dermatology, University of Würzburg, Germany.
Hamm
H
H
Wever
S
S
Hashimoto
T
T
Schröder
U
U
Bröcker
E B
EB
Zillikens
D
D
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D019085:Fluorescent Antibody Technique, Direct; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010118:Oxytetracycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D019233:Retreatment
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D007074:Immunoglobulin G; D009536:Niacinamide; D002990:Clobetasol; D010118:Oxytetracycline